CEOWORLD magazine

5th Avenue, New York, NY 10001, United States
Phone: +1 3479835101
Email: info@ceoworld.biz
+1 (646) 466-6530 info@ceoworld.biz
Tuesday, November 17th, 2026 1:57 AM
Home » Global Executives » Billionaire Ken Griffin’s Citadel Builds a $900 Million Bet on AbbVie
Global Executives

Billionaire Ken Griffin’s Citadel Builds a $900 Million Bet on AbbVie

Billionaire Ken Griffin

Billionaire Ken Griffin’s Citadel Advisors made one of its more notable pharmaceutical moves of the year in the second quarter. It bought about 2.7 million shares of AbbVie at an average price of about $235, an outlay of roughly $633 million. The purchase took Citadel’s holding to about 3.2 million shares, up from roughly half a million at the start of the quarter.

The timing has worked so far. AbbVie shares now trade at about $284, about 21% above Citadel’s average purchase price and up about 24% this year. At that price, Citadel’s disclosed stake is worth about $909 million.

The position is still small for Citadel. At the end of June, it represented less than half of one percent of the firm’s reported U.S. equity holdings. But the size and pace of the increase make it a useful case study in how one of the world’s most sophisticated investment firms is positioning in large-cap healthcare.

Reading a Citadel Filing Correctly

Quarterly 13F disclosures need to be interpreted carefully, particularly for a firm like Citadel. It is a multi-strategy hedge fund in which dozens of independent portfolio teams run long and short positions, often hedged against each other. A 13F shows only long U.S. equity holdings and certain options at quarter-end. It does not show short positions, hedges, or what has happened since.

The AbbVie stake may therefore represent a directional view, one leg of a paired trade within the healthcare sector, or a position already adjusted after June 30. Griffin has said publicly that Citadel reduced risk across its portfolio this year through large block sales. Citadel’s third-quarter filing, due by mid-November, will show whether the AbbVie position was maintained.

What the filing does show is that Citadel’s portfolio teams were willing to commit substantial capital to AbbVie at around $235 a share.

Life After Humira

AbbVie’s investment case rests on how it handled one of the largest patent expirations in pharmaceutical history. Humira, its rheumatoid arthritis and immunology drug, was for years the world’s best-selling medicine. It faced U.S. biosimilar competition from 2023, and its sales have fallen sharply since.

AbbVie’s response was to build two successors, Skyrizi and Rinvoq, which have more than replaced Humira’s peak sales. In the second quarter of 2026, Skyrizi generated about $5.5 billion in sales, up 24% from a year earlier, and Rinvoq about $2.5 billion, up nearly 24%. Total revenue reached about $17 billion, up 10%.

Management has raised its full-year forecast twice this year. It now expects revenue of about $67.6 billion and adjusted earnings of $13.87 to $14.07 per share. Neuroscience, including migraine treatments and Botox Therapeutic, is expected to contribute about $12.7 billion.

The Parkinson’s Catalyst

In late September, the U.S. Food and Drug Administration approved Juvmo (tavapadon), a once-daily oral treatment for Parkinson’s disease that came from AbbVie’s 2024 acquisition of Cerevel Therapeutics. It is the first approved drug to selectively target the brain’s D1 and D5 dopamine receptors.

“The approval of Juvmo marks the first dopaminergic breakthrough for Parkinson’s disease in decades,” said Roopal Thakkar, AbbVie’s chief scientific officer.

Some analysts expect Juvmo’s annual sales to reach as much as $1.4 billion by 2040. That is meaningful but modest next to AbbVie’s immunology franchise. Its strategic value lies more in confirming the company’s push into neuroscience, a growth area as populations age. AbbVie also has about 90 programs in development, around two-thirds of them in late-stage trials, and has added immunology and respiratory candidates through its acquisition of Apogee Therapeutics.

The Dividend and the Valuation

AbbVie is one of the market’s most prominent dividend payers. Its current quarterly dividend of $1.73 equals $6.92 a year, a yield of about 2.4% at the current share price. Including its history as part of Abbott Laboratories before the 2013 spin-off, the company has raised its dividend for more than 50 consecutive years, which qualifies it as a “Dividend King.” It has typically announced its annual increase in late October.

Its trailing price-to-earnings ratio of about 74 looks expensive, but it is misleading. AbbVie’s reported earnings are depressed by large non-cash charges tied to acquisitions and acquired research. On management’s adjusted earnings guidance, the shares trade at about 20 times this year’s earnings, close to the large-cap pharmaceutical average.

Analysts are largely positive. Of the 30 tracked by one major platform, 24 rate the stock a buy or strong buy.

The Risks

The bullish case has clear counterweights:

  • Pricing pressure. AbbVie has pointed to low-single-digit price erosion in immunology as it negotiates 2027 contracts with U.S. payers. The Inflation Reduction Act’s Medicare price negotiation adds longer-term risk to its largest drugs.
  • Concentration. Skyrizi and Rinvoq now drive most of AbbVie’s growth. Any clinical, competitive or regulatory setback would hit them hard.
  • Weak spots. Aesthetics, including Botox Cosmetic and dermal fillers, remains soft, and oncology sales, notably Imbruvica, are declining.
  • Leverage. Acquisitions, including Apogee, add interest costs and some earnings dilution.
  • The rally itself. After a 24% gain this year, much of the good news is already reflected in the share price.

Why This Matters for Business Leaders

Patent cliffs can be managed. AbbVie’s replacement of Humira with Skyrizi and Rinvoq is one of the most successful product transitions in the industry. It shows that pipeline investment made years ahead of loss of exclusivity can protect enterprise value.

Institutional filings are signals, not instructions. Citadel’s buying indicates professional conviction at a point in time, but multi-strategy filings omit hedges and shorts, so they should not be read as simple endorsements.

Healthcare offers defensive growth. At a time of concern about valuations in artificial intelligence and technology, large pharmaceutical companies with strong cash flows and dividends are attracting capital as a balance to growth-heavy portfolios.

Executive Takeaways

What changed: Citadel increased its AbbVie holding more than sixfold in the second quarter, to about 3.2 million shares now worth roughly $909 million, ahead of a 21% gain in the shares.

Why it matters: The move points to institutional confidence in AbbVie’s post-Humira growth, its neuroscience expansion and its dividend record, at a reasonable valuation on adjusted earnings.

What leaders should do next: Treat 13F disclosures as a starting point for research rather than a conclusion, and weigh AbbVie’s growth against pricing pressure and concentration risk before allocating capital.

What to Watch

Over the next 12 to 24 months, the key indicators are AbbVie’s third-quarter results and any dividend increase in the coming days, Citadel’s mid-November filing, Juvmo’s commercial launch, hidradenitis suppurativa trial data for Rinvoq and lutikizumab, the FDA’s decision on Skyrizi in Crohn’s disease, and the outcome of U.S. drug pricing negotiations. AbbVie has shown it can replace a blockbuster. The next test is whether it can sustain growth that depends so heavily on two drugs.

Have you read?
Egypt Citizenship-by-Investment Program. Grenada Citizenship-by-Investment Program.
Jordan Citizenship-by-Investment Program. Malta Citizenship by Merit Program. Nauru Citizenship-by-Investment Program.

Share this article:
Follow CEOWORLD Magazine on Google News

Follow CEOWORLD Magazine on: Google News, LinkedIn, X (Twitter), and Facebook.

Note: The views expressed are those of the authors and do not necessarily reflect those of CEOWORLD Magazine, its Editorial Board, or management. Content is provided "as is," may contain monetized links, and is not professional advice. See our Ethics & Guidelines for details. Reproduction requires prior written permission.

Contact info@ceoworld.biz for inquiries or media requests.

Alexandra Dimitropoulou, PhD
Dr. Alexandra Dimitropoulou, PhD in Cross-Cultural Media Innovation & Global Editorial Strategy, is Senior Business and Finance Editor at CEOWORLD Magazine, specialising in global markets, corporate finance, M&A, investment strategy, and executive leadership. With more than 12 years of experience across financial journalism and corporate strategy, she brings a… Read Alexandra Dimitropoulou, PhD’s full executive profile here →